cat no | io1022
ioGlutamatergic Neurons GBA null/N409S
Human iPSC-derived Gaucher and Parkinson’s disease model
-
Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days
-
Engineered to carry a GBA mutation relevant for modelling Gaucher and Parkinson's diseases
-
Consistent, functional excitatory neurons that form neuronal networks within days
Place your order
Human iPSC-derived Gaucher and Parkinson’s disease model
Representative ICC staining of ioGlutamatergic Neurons GBA null/N409S; MAP2 (red), VGLUT2 (green), DAPI (blue).
ioGlutamatergic Neurons Media Kit
Cell culture media kit for the culture of ioGlutamatergic Neurons up to 14 days post-thaw
Reduced glucocerebrosidase activity demonstrated in disease model cells carrying GBA mutations
Glucocerebrosidase (GCase) activity was measured in ioGlutamatergic Neurons carrying mutations in the GBA gene (GBA null/R159W, GBA null/null and GBA null/N409S) or carrying SNCA A53T mutations (SNCA A53T/A53T and SNCA A53T/WT), and the wild-type genetically matched control.
Cells were seeded in 96-well plates (25,000 cells per well) and a fluorometric assay using 4-MUG as substrate was carried out on DIV9 to measure the enzymatic activity of GCase.
The assay confirmed that iPSC-derived glutamatergic neurons with GBA mutations showed significantly reduced GCase activity compared to the wild-type control and SNCA A53T disease models.
Statistical analysis: One-way ANOVA followed by Dunnett’s multiple comparison test versus isogenic control ***p<0.001.
Data courtesy of T. Loeffler et al., Scantox
ioGlutamatergic Neurons GBA null/N409S express neuron-specific markers comparably to the wild-type control
Immunofluorescent staining on day 11 post-thaw demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/N409S compared to the genetically matched control (10X objective).
ioGlutamatergic Neurons GBA null/N409S form structural neuronal networks by day 11
ioGlutamatergic Neurons GBA null/N409S mature rapidly and form structural neuronal networks over 11 days, when compared to the genetically matched control. Day 1 to 11 post thaw; 10X objective.
Advanced tri-culture of ioGlutamatergic Neurons, ioAstrocytes 2.0, and ioMicroglia
While neuronal-astrocyte co-cultures capture essential structural and metabolic synergy, the addition of microglia, the resident myeloid cells of the CNS, is critical for accurately modelling neuroinflammatory pathways, synaptic pruning, and homeostatic maintenance.
This representative immunocytochemistry image demonstrates a successful tri-culture established at a 2:1:2 ratio (neurons:astrocytes:microglia). Using an optimised bit.bio protocol for 24-well plates, the tri-culture can be robustly maintained for up to 7 days. Staining with cell type-specific markers confirms the presence and integration of all three populations, shown alongside single-channel panels: MAP2-positive ioGlutamatergic Neurons (red), S100B-positive ioAstrocytes 2.0 (cyan), and IBA1-positive ioMicroglia (yellow); with DAPI as a nuclear counterstain (blue). Scale bars: 200 µm.
Efficient mRNA transfection into ioGlutamatergic Neurons
ioGlutamatergic Neurons are efficiently transfected and show sustained long-term expression of mRNA encoding GFP. ioGlutamatergic Neurons were imaged from day 1 post-thaw and throughout the experiment to assess transfection efficiency and evaluate potential cytotoxic effects of the transfection protocol. Day 1 images were captured prior to transfection on the same day.
Download the step-by-step protocol for lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons.
Lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons
ioGlutamatergic Neurons were transfected 24 hours post-thaw using Lipofectamine™ Stem Transfection Reagent. The transfection efficiency was evaluated by fluorescence imaging over 18 days after mRNA delivery, resulting in high transfection efficiency (close to 100%) and long-term sustained GFP expression.
Quantification of the GFP signal shows a decrease in GFP intensity over time, while the percentage of GFP-positive cells remains largely unchanged over time.
(A) The percentage of GFP-positive cells from two independent experiments.
(B) GFP intensity, quantified in successfully transfected cells from two independent experiments is quantified and normalised to day 2 (24 hours post-transfection).
Vial limit exceeded
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
ioGlutamatergic Neurons GBA null/N409S are opti‑ox deterministically programmed excitatory neurons carrying a genetically engineered compound heterozygous mutation in the GBA gene encoding the glucocerebrosidase (GCase) enzyme. These cells offer a rapidly maturing, human cell model to investigate modulation of GCase expression.
This variant, historically known as N370S, is now designated N409S under standardised nomenclature that accounts for the protein's 39-amino acid signal peptide.
Related Parkinson's disease model cells are available with GBA null/R159W, PINK1 Q456X, PRKN R275W and SNCA A53T mutations, and all can be used alongside their genetically matched control, ioGlutamatergic Neurons.
Benchtop benefits
Make true comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type control to investigate the impact of the GBA mutation on molecular mechanisms and cell function.
Scalable
With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and wil-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Cells arrive ready to plate

ioGlutamatergic Neurons GBA null/N409S are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast),
Genotype APOE 3/4
Vial size
Small: >1 x 106 viable cells
Quality control
Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
30,000 cells/cm2
User storage
LN2 or -150°C
Format
Cryopreserved cells
Genetic modification
Compound heterozygous null/N409S mutation in the GBA gene
Applications
Gaucher and Parkinson's disease research
Drug discovery and development
Disease modelling
Product use
ioCells are for research use only
Scale your study with volume pricing
Enabling scientists to use human cells in their research, running additional experiments without rationing cells or limiting experimental scale
| Order quantity | Total vials received | Pricing tier |
| 1 - 9 packs | 3 - 27 vials | Standard price |
| 10 - 33 packs | 30 - 99 vials | Automatic 10% discount |
| > 34 packs | > 100 vials | > Contact us for a quote |
Disease-related phenotype
Reduced glucocerebrosidase activity demonstrated in disease model cells carrying GBA mutations
Glucocerebrosidase (GCase) activity was measured in ioGlutamatergic Neurons carrying mutations in the GBA gene (GBA null/R159W, GBA null/null and GBA null/N409S) or carrying SNCA A53T mutations (SNCA A53T/A53T and SNCA A53T/WT), and the wild-type genetically matched control.
Cells were seeded in 96-well plates (25,000 cells per well) and a fluorimetric assay using 4-MUG as substrate was carried out on DIV9 to measure the enzymatic activity of GCase.
The assay confirmed that iPSC-derived glutamatergic neurons with GBA mutations showed significantly reduced GCase activity compared to the wild-type control and SNCA A53T disease models.
Statistical analysis: One-way ANOVA followed by Dunnett’s multiple comparison test versus isogenic control ***p<0.001.
Data courtesy of T. Loeffler et al., Scantox
Highly characterised and defined
ioGlutamatergic Neurons GBA null/N409S express neuron-specific markers comparably to the wild-type control
Immunofluorescent staining on day 11 post-thaw demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/N409S compared to the genetically matched control (10X objective).
ioGlutamatergic Neurons GBA null/N409S form structural neuronal networks by day 11
ioGlutamatergic Neurons GBA null/N409S mature rapidly and form structural neuronal networks over 11 days, when compared to the genetically matched control. Day 1 to 11 post thaw; 10X objective.
Industry leading seeding density
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar commercially available products. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Get started with
How to culture ioGlutamatergic Neurons
In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.
How to prepare tissue culture vessels with PDL-Geltrex for culture
Dr Kaiser Karim will take you through the step-by-step process of coating your culture plate with PDL-Geltrex before the revival of ioGlutamatergic Neurons.
Since recording this video Geltrex has been replaced by Geltrex Flex; refer to the user manual for full details.
Frequently Asked Questions (FAQs)
How was the GBA null/N409S genotype engineered?
The starting point for all ioGlutamatergic Neurons disease models is the parental opti-ox-enabled iPS cell line. CRISPR/Cas9 gene editing was used to introduce the null/N409S mutation. Genotyping confirmed that the null allele has a 55 base pair heterozygous deletion located in coding exon 9, causing a premature stop codon that disrupts the enzyme's active site across domains II and III. The second allele has a missense mutation, N409S (NM_000157.4(GBA1):c.1226A>G (p.Asn409Ser)).
Why is the N409S mutation in the GBA gene relevant for disease modelling?
Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson’s disease (PD) and Lewy body dementia (LBD). In addition, Gaucher disease, an autosomal recessive disorder, is driven by bi-allelic GBA1 mutations. In patients, a pronounced deficit in glucocerebrosidase (GCase) activity drives severe lysosomal dysfunction and enhanced alpha-synuclein pathology. ioGlutamatergic Neurons carrying a compound heterozygous GBA null/N409S mutation pair a functionally absent allele with the most prevalent clinical missense mutation. By expressing this genotype in translationally relevant human excitatory neurons, this model offers an opportunity to screen GCase activators, gene therapies, and treatments targeting lysosomal storage and neurodegeneration.
Is there a genetically-matched wild-type control that can be used alongside the GBA disease model in human iPSC-derived glutamatergic neurons?
bit.bio offers the GBA null/N409S disease model and a genetically-matched wild-type control, which together provide a physiologically-relevant in vitro cell model to investigate the impact of the modulation of GCase expression.
Documentation
Product resources
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Wild Type and Isogenic Disease Model cells: A true comparison.
Further your disease research by pairing our wild type cells with isogenic disease models.
ioCells catalogue
Human iPSC-derived cells
powered by opti-ox
Consistent. Defined. Scalable.